Key result
An experimental oral rhesus rotavirus vaccine demonstrated effectiveness (virus shedding or serologic response) in 82% of vaccinated children, with no clinical illness compared to concurrent controls.
Why the study?
Does an experimental live attenuated rotavirus vaccine induce a serologic response or virus shedding without causing clinical illness in children?
Does an experimental live attenuated rotavirus vaccine induce a serologic response or virus shedding without causing clinical illness in children?
The rhesus rotavirus-MMU-18006 vaccine is safe and effective at inducing a serologic response or virus shedding in children, representing a promising step for immunoprophylaxis.
Answers are grounded in this paper and cite their sources.
Supports immunogenicity without illness in children; leaves open efficacy confirmation in randomized trials.
Fifty children, 3 months to 12 years of age, were given an experimental, orally administered, live attenuated rotavirus vaccine. Overall evidence of vaccine effectiveness as judged by vaccine virus shedding or a serologic response was seen in 82% of vaccinees. No clinical illness was seen in the rotavirus vaccinees when compared with 40 concurrently studied control children. No transmission to control children was observed even with close daily contact in a day-care setting. Young infants, generally less than 1 year of age, who had not previously experienced wild-type rotavirus infection shed significantly more vaccine virus. Limitation of virus shedding in those already exposed may be related to a prompt copro-IgA response which was significantly elevated by three days after vaccination. In summary, the development of this rotavirus vaccine, rhesus rotavirus-MMU-18006, is a promising step in the development of immunoprophylaxis against this major enteric pathogen.
No takes yet. Share an insight, caveat, or question.
Tajima et al. (1987) studied Healthy children (rotavirus immunoprophylaxis) (n=90). Experimental oral live attenuated rotavirus vaccine (rhesus rotavirus-MMU-18006) vs. Concurrent control children was evaluated on Vaccine effectiveness as judged by vaccine virus shedding or a serologic response. An experimental oral rhesus rotavirus vaccine demonstrated effectiveness (virus shedding or serologic response) in 82% of vaccinated children, with no clinical illness compared to concurrent controls.
Synapse has enriched 10 related papers. Consider them for comparative context: